AFA. V. Faenson

A. V. Faenson

*This is an algorithmically generated author record based on publicly available information.

A. V. Faenson has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Gender specificity of angiogenesis in patients with non-muscle invasive bladder cancer complicated by type 2 diabetes mellitus

    by E.M. Ataeva, E.P. Ulyanova, A.B. Sagakyants, I.V. Kaplieva, O.G. Shulgina, E.N. Chernikova, D.A. Shvyrev, V.K. Khvan, A.V. Faenson

    Cancers and diabetes mellitus are among the most common human pathologies, with an increase in morbidity every year. To this date, a relationship of type 2 diabetes mellitus (DM2) with increased risk of development and progression of cancer of many localizations has been established, nevertheless the data on the impact of DM2 on the course of bladder cancer are contradictory. Objective. To study the features of expression of angiogenic proteins — vascular endothelial growth factor (VEGF) and platelet endothelial cell adhesion molecule (CD31), to evaluate their gender specificity in non-muscle-invasive bladder cancer, developing in addition to type 2 diabetes mellitus 2, compared with these indicators in bladder cancer emerging without comorbid pathology. Materials and methods. The study was conducted on material of 40 patients of both sexes with a verified urothelial non-muscle-invasive bladder cancer who were treated at «NMRC for Oncology» (Rostov-on-Don) from 2017 to 2022. Monoclonal mouse antibodies to VEGF and CD31 were used for immunohistochemical analysis. Percentage of tumor cells expressing VEGF and number of vessels stained with CD31 marker were determined. Results. A statistically significant exceedance of VEGF expression level by 2.8 times has been noted in patients of the group with DM2 compared to women in the same group (p=0.002) and men without comorbid pathology (p=0.001). The number of CD31-stained vessels was 1.3 times (p=0.042) higher in women of the same group than in men, and 3 times (p=0.009) higher in women without comorbid pathology. Conclusion. The revealed gender specificity of expression of angiogenesis markers in non-muscle-invasive bladder cancer, developing in addition to type 2 diabetes mellitus, can be considered for the prediction of risk of development and progression of this pathology.

  • Open Access

    Intravenous radionuclide therapy with radium chloride [223Ra] in patients with bone metastases from castration-resistant prostate cancer

    by O. I. Kit, N. A. Maksimova, M. A. Gusareva, A. N. Shevchenko, M. S. Zinkovich, M. G. Ilchenko, K. P. Boyko, A. V. Faenson, S. N. Dimitriadi, L. Ya. Rozenko

    Purpose of the study. Assessment of clinical safety and effectiveness of radium‑223 in patients with bone metastases from castration-resistant prostate cancer.Patients and methods. The study involved materials on 15 patients with bone metastases from castration-resistant prostate cancer aged 58–81 years, with the mean age of 67.2 ± 6.5 years, who were examined and received full treatment with 6 intravenous injections of radium‑223 chloride [223Ra] at the National Medical Research Centre for Oncology. Most patients (73.3 %) showed ECOG 1 performance status. Pain syndrome before the treatment was registered in 12 (80 %) patients.Results. Evaluation of the tolerability of radium chloride did not show hematological reactions such as anemia and thrombocytopenia. One patient had grade II intestinal toxicity after the 3rd injection managed with medication. Assessment of indirect signs of the treatment effectiveness demonstrated that 6 people showed an increase in PSA during treatment, while alkaline phosphatase levels were within normal range indicating no bone destruction. 8 of 12 patients with pain syndrome showed its relief during the therapy. The following results were obtained during a follow-up examination after 3 months in 15 patients who received the full treatment course: stabilization in 8 patients; improvement in 4 patients with decreased metabolic activity and lower numbers of metastatic foci; progression with the appearance of new metastatic foci in the bones in 3 patients.Conclusion. Radium chloride showed good results in the treatment of patients with bone metastases from castration-resistant prostate cancer. Low toxicity and improvement in the quality of life by pain relief make this treatment technique promising.